Biosimilars: Key Insights on the Evolving Biopharmaceutical Landscape
Jason W. Bernstein
Epocrates Lead Strategist athenahealth
Ready or not, here biosimilars come
Biosimilars have inspired cost-saving hopes in the US, provoked biopharmaceutical legal battles, and raised concerns about treatment switches. With the FDA approving five biosimilars in two years, biosimilars are now right outside our doorstep. Join Jason Bernstein, Lead Strategist at Epocrates as he discusses what positions you could take and what we must keep in mind as the US biopharmaceutical landscape transforms.
Biosimilars are the “generic version” of biologics—when did biologics start dominating the Top 10 Selling Drug list?
Why is each biosimilar marketed and prescribed as a new drug—unlike the generic version of small-molecule drugs?
How may prescribing habits change if prime areas of information gaps— clinical evidence, cost, and legislation —are addressed? Real-world data have shown both prescribers and consumers thirsting for more information.
About the Speaker:
Jason W. Bernstein, Epocrates Lead Strategist, athenahealth
Jason draws from 15 years of immersion in the medical communications field, working alongside US, European and Asia-based firms as well as international panels of key opinion leaders, regional medical societies and local healthcare professionals, to execute multi-channel outreach programs. Currently based in the biomedical-tech hub of Boston, Jason’s role as lead strategist at Epocrates is to engage biopharmaceutical firms on their targeted communication campaigns, with real-world outcomes as an aim.